Coy Travis Alan 4

What Happened

• Travis A. Coy, Chief Financial Officer of Immunocore Holdings plc (IMCR), received two equity awards on February 17, 2026: 33,353 restricted share units (RSUs) and 95,637 additional derivative awards (treated as an option-style award). Both grants were reported as acquisitions at $0.00 (i.e., compensation awards, not purchases or sales). The combined total granted was 128,990 units. The filing does not state an immediate cash value or any contemporaneous sale.

Key Details

• Transaction date: February 17, 2026; Form 4 filed February 19, 2026 (appears timely).
• Grant amounts and price: 33,353 RSUs @ $0.00; 95,637 derivative/option-style units @ $0.00.
• Shares owned after transaction: not specified in the information provided in this summary.
• Footnotes of note:
  • F1: Each RSU represents a contingent right to receive one ordinary share.
  • F2: RSUs vest in four equal annual installments beginning Feb 17, 2027, subject to continued service.
  • F4: Option-style award vests 25% on Feb 17, 2027, then 6.25% quarterly thereafter, subject to continued service.
  • F3: Ordinary shares may be represented by American Depositary Shares (each ADS = 1 ordinary share).
• No 10b5-1 plan, tax-withholding sale, or late-filing flag was reported in the filings provided.

Context

• These were compensation grants (derivative awards) with multi-year vesting schedules — not open-market purchases or immediate sales. RSUs convert to shares only as they vest; the option-style award vests over time, so any future share receipt depends on continued service and vesting.
• Such grants are routine executive compensation; they do not, by themselves, indicate a near-term buy or sell decision.